M

Monte Rosa Therapeutics

Develops targeted protein degraders for therapy

Senior Scientist - Toxicology

Regulatory & Quality (Life Sciences)Posted on Nov 13
Full-timeBasel, SwitzerlandCHF130k - CHF155kIn-person

About the Job

Requirements

  • A PhD degree or DVM and 5 years of scientific experience, or a Master's degree and 10 years of scientific experience in preclinical toxicology and drug development in the pharmaceutical or biotechnology sector.
  • Familiarity with Good Laboratory Practice regulations and International Council for Harmonisation and Organisation for Economic Co-operation and Development guidelines, and FDA and EMA requirements for conducting toxicology studies to support regulatory filings.
  • Experience working with contract research organizations.
  • Ability to develop and deliver clear and concise presentations for internal and external meetings.
  • Outstanding written and verbal communication skills.

Responsibilities

  • Direct nonclinical safety and toxicology work for programs to enable drug candidates through discovery and development.
  • Contribute to research and development strategy by designing, conducting, or overseeing studies; analyzing and interpreting results; and ensuring quality documentation and record keeping for nonclinical activities.
  • Support global regulatory activities for nonclinical filing sections, including Investigational New Drug applications, annual reports, Investigator Brochures, and New Drug Applications.
  • Interact with multidisciplinary teams, including biology, medicinal chemistry, CMC, DMPK, and clinical science, to advance discovery candidates into development.
  • Support regulatory toxicology activities as an extension of the position.
  • Help evolve hit identification and hit-to-lead activities by adopting novel assay technologies, enhancing processes, and driving internal and external partnerships.
  • Develop toxicology studies for Molecular Glue Degraders by bridging the platform to understand and de-risk potential issues.
  • Work cross-functionally and across cultures with departments on in vitro and in vivo models, integrating toxicological data to help mitigate findings.
  • Participate in designing early in vitro toxicity screening and/or secondary or safety pharmacology studies for small molecules in preclinical research and development.
  • Implement and manage studies with contract research organizations and/or academic collaborators.
  • Execute studies addressing mechanistic issues and/or unexpected adverse findings in preclinical or clinical trials, and provide results promptly to project teams and leadership.
  • Select contract research organizations and represent the company as Study Monitor for in vitro and in vivo toxicology studies.
  • Design protocols and review protocol amendments.
  • Review experimental data, ensure timely delivery of toxicology reports for regulatory submissions, and assist in preparing safety pharmacology and toxicology sections for Investigational New Drug applications, Investigator Brochures, and New Drug Applications.

Desired Qualifications

  • ERT or DABT certification is preferred.

About the Company

Monte Rosa Therapeutics

Develops targeted protein degraders for therapy

Monte Rosa Therapeutics develops molecular glue degraders (MGDs) to treat cancer and autoimmune/inflammatory diseases using its QuEEN discovery engine, a platform that fuses AI-guided chemistry, proteomics, and structural biology to design MGDs. MGDs work by bringing a target protein together with an E3 ligase, tagging the protein for destruction by the cell's proteasome rather than just inhibiting it. The company distinguishes itself with the QuEEN platform, partnerships with Roche and Novartis for joint development and funding, and a portfolio that includes MRT-2359, MRT-6160, and MRT-8102 as clinical-stage programs. Its goal is to discover, develop, and commercialize MGDs, grow its pipeline, and create value through collaborations, upfront payments, milestones, and royalties while delivering treatments for patients with serious diseases.

Company size
201-500
Company stage
IPO
Headquarters
Boston, MA
Founded
2018

Recently Posted Jobs

Explore more opportunities at Monte Rosa Therapeutics

See more jobs